STXS Stock Forecast 2025-2026
Distance to STXS Price Targets
STXS Price Momentum
10 Quality Stocks Worth Considering Now
Researching Stereotaxis (STXS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on STXS and similar high-potential opportunities.
Latest STXS Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, STXS has a bullish consensus with a median price target of $4.50 (ranging from $4.00 to $5.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.83, the median forecast implies a 145.9% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Wittes at Roth MKM, projecting a 173.2% upside. Conversely, the most conservative target is provided by Frank Takkinen at Lake Street, suggesting a 118.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STXS Analyst Ratings
STXS Price Target Range
Latest STXS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STXS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $4.00 |
| Mar 5, 2024 | Roth MKM | Jason Wittes | Buy | Reiterates | $5.00 |
| Jan 10, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $5.00 |
| Mar 6, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $4.00 |
| Mar 6, 2023 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $5.50 |
| Mar 6, 2023 | Piper Sandler | Adam Maeder | Overweight | Maintains | $5.00 |
| Nov 11, 2022 | Cowen & Co. | Joshua Jennings | Outperform | Maintains | $5.00 |
| Sep 2, 2022 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Jul 12, 2022 | Aegis Capital | Nathan Weinstein | Buy | Initiates | $6.00 |
| Jun 23, 2022 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Jan 5, 2022 | Loop Capital | Buy | Initiates | $0.00 | |
| Jan 5, 2022 | Craig-Hallum | Buy | Initiates | $0.00 | |
| May 26, 2021 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Sep 8, 2020 | Northland Capital Markets | Outperform | Initiates | $0.00 | |
| Apr 9, 2020 | Cowen & Co. | Outperform | Initiates | $0.00 |
Stereotaxis Inc. (STXS) Competitors
The following stocks are similar to Stereotaxis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stereotaxis Inc. (STXS) Financial Data
Stereotaxis Inc. has a market capitalization of $156.14M with a P/E ratio of -6.8x. The company generates $26.92M in trailing twelve-month revenue with a -89.3% profit margin.
Revenue growth is +38.9% quarter-over-quarter, while maintaining an operating margin of -120.3% and return on equity of -144.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Stereotaxis Inc. (STXS) Business Model
About Stereotaxis Inc.
Specializes in robotic systems for surgery.
The company develops and commercializes robotic navigation technologies, particularly for cardiac arrhythmia treatments. It generates revenue primarily through the sales of its flagship product, the Niobe Magnetic Navigation System, which enhances surgical precision and safety, thereby attracting hospitals and medical centers focusing on interventional cardiology.
Stereotaxis is based in St. Louis, Missouri, and is positioned as a leader in the robotic surgery sector, contributing to advancements in the medical device industry that aim to improve patient outcomes and healthcare efficiency.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
122
CEO
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Country
United States
IPO Year
2004
Website
www.stereotaxis.comStereotaxis Inc. (STXS) Latest News & Analysis
Stereotaxis (NYSE: STXS) CEO David Fischel will speak at the 37th Annual ROTH Conference in Dana Point, California, highlighting the company's role in surgical robotics.
David Fischel’s participation in a prominent conference may boost Stereotaxis's visibility, potentially attracting investors and influencing stock performance.
STXS has submitted the MAGiC Sweep, a robotically navigated high-density EP mapping catheter, for FDA clearance, advancing cardiac arrhythmia treatment.
STXS's submission for FDA clearance could lead to market approval, potentially increasing sales and market share in the cardiac treatment sector, positively impacting stock performance.
Management's conservative 2025 sales guidance aims to address bearish investor concerns, focusing on existing system backlog and MAGiC's recurring revenue potential in Europe.
Management's conservative sales guidance indicates achievable targets, potentially boosting investor confidence. The focus on recurring revenue from MAGiC Sweep highlights growth opportunities in robotics.
Stereotaxis, Inc. (STXS) held its Q4 2024 earnings call, discussing financial results and company performance. Further details are available in the full transcript.
The earnings call provides insights into Stereotaxis' financial performance, strategic direction, and future growth prospects, impacting stock valuation and investor sentiment.
Stereotaxis (NYSE: STXS) reported its fourth quarter and full year financial results for 2024, as of March 3, 2025. Further details on performance are forthcoming.
Stereotaxis' financial results can indicate its growth, profitability, and market position in surgical robotics, impacting stock performance and investor sentiment.
Stereotaxis Inc. (STXS) reported a quarterly loss of $0.09 per share, worse than the expected loss of $0.05, and higher than the $0.07 loss per share from the previous year.
Stereotaxis Inc.'s larger-than-expected quarterly loss may signal ongoing operational challenges, potentially impacting investor confidence and stock performance.
Frequently Asked Questions About STXS Stock
What is Stereotaxis Inc.'s (STXS) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Stereotaxis Inc. (STXS) has a median price target of $4.50. The highest price target is $5.00 and the lowest is $4.00.
Is STXS stock a good investment in 2025?
According to current analyst ratings, STXS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STXS stock?
Wall Street analysts predict STXS stock could reach $4.50 in the next 12 months. This represents a 145.9% increase from the current price of $1.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stereotaxis Inc.'s business model?
The company develops and commercializes robotic navigation technologies, particularly for cardiac arrhythmia treatments. It generates revenue primarily through the sales of its flagship product, the Niobe Magnetic Navigation System, which enhances surgical precision and safety, thereby attracting hospitals and medical centers focusing on interventional cardiology.
What is the highest forecasted price for STXS Stereotaxis Inc.?
The highest price target for STXS is $5.00 from Jason Wittes at Roth MKM, which represents a 173.2% increase from the current price of $1.83.
What is the lowest forecasted price for STXS Stereotaxis Inc.?
The lowest price target for STXS is $4.00 from Frank Takkinen at Lake Street, which represents a 118.6% increase from the current price of $1.83.
What is the overall STXS consensus from analysts for Stereotaxis Inc.?
The overall analyst consensus for STXS is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are STXS stock price projections?
Stock price projections, including those for Stereotaxis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
